WO2022152236A1 - 抗trpv6单克隆抗体及其应用 - Google Patents

抗trpv6单克隆抗体及其应用 Download PDF

Info

Publication number
WO2022152236A1
WO2022152236A1 PCT/CN2022/071976 CN2022071976W WO2022152236A1 WO 2022152236 A1 WO2022152236 A1 WO 2022152236A1 CN 2022071976 W CN2022071976 W CN 2022071976W WO 2022152236 A1 WO2022152236 A1 WO 2022152236A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
seq
antigen
binding fragment
trpv6
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2022/071976
Other languages
English (en)
French (fr)
Chinese (zh)
Inventor
黄保华
谭巍
王中波
王伟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Coherent Biopharma Suzhou Co Ltd
Original Assignee
Coherent Biopharma Suzhou Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Coherent Biopharma Suzhou Co Ltd filed Critical Coherent Biopharma Suzhou Co Ltd
Priority to CN202280010293.4A priority Critical patent/CN116802277A/zh
Priority to CA3206472A priority patent/CA3206472A1/en
Priority to KR1020237022218A priority patent/KR20230132450A/ko
Priority to EP22739112.5A priority patent/EP4293044A4/en
Priority to US18/261,489 priority patent/US20260116965A1/en
Priority to JP2023542926A priority patent/JP2024505430A/ja
Publication of WO2022152236A1 publication Critical patent/WO2022152236A1/zh
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels

Definitions

  • the present invention relates to a series of antibodies that can recognize human TRPV6 protein and a hybridoma cell line that can secrete the series of antibodies.
  • the present invention provides a series of monoclonal antibodies that specifically bind to TRPV6 molecules in tumor cell membranes/plasma, and the amino acid sequences of the variable regions of the heavy and light chains of the antibodies and the DNA sequences encoding the variable regions have been determined , the antibody or its antigenic fragment can be used for immunohistochemistry (IHC), enzyme-linked immunosorbent (ELISA), immunofluorescence (IF), chemiluminescence (CLIA), immunoturbidimetry (TIA) by manual or automated means or Western blotting (Western Blot) method to detect the level of TRPV6 in cells, so as to be used in the method for diagnosing these tumors, which belongs to the field of biological detection.
  • IHC immunohistochemistry
  • ELISA enzyme-linked immunosorbent
  • IF immunofluorescence
  • CLIA chemiluminescence
  • Transient receptor potential cation channel subfamily V member 6 is a highly selective calcium ion transmembrane transport channel that mediates the active transport of calcium ions from extracellular to intracellular .
  • TRPV6 is expressed in normal human kidneys, gastrointestinal tract, pancreas, breast, salivary glands, etc., but is mainly expressed in intestinal epithelial cells, which are involved in the transport of calcium ions into cells, so when the number or function of TRPV6 channels changes , which can cause changes in calcium regulation and further lead to structural or functional abnormalities of related tissues and organs.
  • TRPV6 Compared with normal tissues, the expression of TRPV6 is significantly increased in breast cancer, bile duct cancer, ovarian cancer, lung squamous cell carcinoma, prostate cancer and other malignant tumors, and its abnormal expression may be related to the formation and progression of tumors.
  • the Prevarskaya team found that calcium uptake by human prostate cancer LNCap cells with high expression of TRPV6 is mediated by TRPV6. After siRNA treatment to down-regulate the level of TRPV6 protein, the number of cells in S phase was reduced and cell proliferation was inhibited.
  • TRPV6 is closely related to a variety of human tumors, and may be related to its regulation of intracellular and extracellular calcium ion concentration changes.
  • TRPV6 As a tumor cell marker, the detection of TRPV6 is of great significance for pathological diagnosis and the use of corresponding targeted drugs. At present, there is no anti-TRPV6 antibody that can be used for diagnosis on the market, and the antibody involved in this patent can fill the gap in this aspect.
  • One aspect of the present application provides an antibody or antigen-binding fragment thereof that specifically binds to TRPV6, wherein the antibody or antigen-binding fragment thereof comprises three heavy chain complementarity determining regions HCDR1, HCDR2 included in the following heavy chain variable regions and HCDR3: heavy chain variable region shown in SEQ ID NO:25; heavy chain variable region shown in SEQ ID NO:27; or heavy chain variable region shown in SEQ ID NO:29.
  • the antibody or antigen-binding fragment thereof comprises three heavy chain complementarity determining regions HCDR1, HCDR2 and HCDR3 selected from the group consisting of: HCDR1 shown in SEQ ID NO:7, HCDR1 shown in SEQ ID NO:8 HCDR2 shown in SEQ ID NO: 9; HCDR1 shown in SEQ ID NO: 13, HCDR2 shown in SEQ ID NO: 14, HCDR3 shown in SEQ ID NO: 15; or HCDR3 shown in SEQ ID NO: 19 HCDR1 shown in SEQ ID NO: 20, HCDR3 shown in SEQ ID NO: 21.
  • the antibody or antigen-binding fragment thereof further comprises three light chain complementarity determining regions LCDR1, LCDR2 and LCDR3 included in the light chain variable region as follows: light chain variable light chain shown in SEQ ID NO: 26 region; the light chain variable region shown in SEQ ID NO:28; or the light chain variable region shown in SEQ ID NO:30.
  • the antibody or antigen-binding fragment thereof further comprises three light chain complementarity determining regions LCDR1, LCDR2 and LCDR3 selected from the group consisting of: LCDR1 shown in SEQ ID NO:10, LCDR1 shown in SEQ ID NO:11 LCDR2 shown in SEQ ID NO: 12 and LCDR3 shown in SEQ ID NO: 12; LCDR1 shown in SEQ ID NO: 16, LCDR2 shown in SEQ ID NO: 17 and LCDR3 shown in SEQ ID NO: 18; LCDR1 shown in SEQ ID NO: 23, LCDR2 shown in SEQ ID NO: 23, and LCDR3 shown in SEQ ID NO: 24.
  • LCDR1, LCDR2 and LCDR3 selected from the group consisting of: LCDR1 shown in SEQ ID NO:10, LCDR1 shown in SEQ ID NO:11 LCDR2 shown in SEQ ID NO: 12 and LCDR3 shown in SEQ ID NO: 12; LCDR1 shown in SEQ ID NO: 16, LCDR2 shown in SEQ ID NO: 17 and LCDR3 shown in SEQ ID
  • the antibody or antigen-binding fragment thereof comprises three heavy chain complementarity determining regions HCDR1, HCDR2 and HCDR3 and three light chain complementarity determining regions LCDR1, LCDR2 and LCDR3 selected from the group consisting of: SEQ ID NO: HCDR1 shown in 7, HCDR2 shown in SEQ ID NO: 8, HCDR3 shown in SEQ ID NO: 9, LCDR1 shown in SEQ ID NO: 10, LCDR2 shown in SEQ ID NO: 11 and SEQ ID NO: LCDR3 shown in 12; HCDR1 shown in SEQ ID NO: 13, HCDR2 shown in SEQ ID NO: 14, HCDR3 shown in SEQ ID NO: 15, LCDR1 shown in SEQ ID NO: 16, SEQ ID NO: LCDR2 shown in 17 and LCDR3 shown in SEQ ID NO: 18; HCDR1 shown in SEQ ID NO: 19, HCDR2 shown in SEQ ID NO: 20, HCDR3 shown in SEQ ID NO: 21, SEQ ID NO: LCDR1 shown in 22,
  • the antibody or antigen-binding fragment thereof comprises HCDR1 set forth in SEQ ID NO:7, HCDR2 set forth in SEQ ID NO:8, HCDR3 set forth in SEQ ID NO:9, SEQ ID NO:10 LCDR1 shown, LCDR2 shown in SEQ ID NO: 11, and LCDR3 shown in SEQ ID NO: 12.
  • the antibody or antigen-binding fragment thereof comprises HCDR1 set forth in SEQ ID NO: 13, HCDR2 set forth in SEQ ID NO: 14, HCDR3 set forth in SEQ ID NO: 15, SEQ ID NO: 16 LCDR1 shown, LCDR2 shown in SEQ ID NO: 17, and LCDR3 shown in SEQ ID NO: 18.
  • the antibody or antigen-binding fragment thereof comprises HCDR1 set forth in SEQ ID NO:19, HCDR2 set forth in SEQ ID NO:20, HCDR3 set forth in SEQ ID NO:21, SEQ ID NO:22 LCDR1 shown, LCDR2 shown in SEQ ID NO: 23, and LCDR3 shown in SEQ ID NO: 24.
  • the antibody or antigen-binding fragment thereof comprises a heavy chain variable region VH selected from the group consisting of: a heavy chain variable region set forth in SEQ ID NO:25; a heavy chain variable region set forth in SEQ ID NO:27 The heavy chain variable region of ; or the heavy chain variable region shown in SEQ ID NO: 29.
  • the antibody or antigen-binding fragment thereof further comprises a light chain variable region VL selected from the group consisting of: a light chain variable region shown in SEQ ID NO:26; a light chain variable region shown in SEQ ID NO:28 The light chain variable region of ; or the light chain variable region shown in SEQ ID NO: 30.
  • the antibody or antigen-binding fragment thereof comprises a heavy chain variable region VH and a light chain variable region VL selected from the group consisting of a heavy chain variable region set forth in SEQ ID NO:25 and Light chain variable region shown in SEQ ID NO:26; heavy chain variable region shown in SEQ ID NO:27 and light chain variable region shown in SEQ ID NO:28; or SEQ ID NO:29 The variable region of the heavy chain and the variable region of the light chain shown in SEQ ID NO: 30.
  • the antibody or antigen-binding fragment thereof comprises a heavy chain variable region set forth in SEQ ID NO:25 and a light chain variable region set forth in SEQ ID NO:26.
  • the antibody or antigen-binding fragment thereof comprises a heavy chain variable region set forth in SEQ ID NO:27 and a light chain variable region set forth in SEQ ID NO:28.
  • the antibody or antigen-binding fragment thereof comprises a heavy chain variable region set forth in SEQ ID NO:29 and a light chain variable region set forth in SEQ ID NO:30.
  • the antibody or antigen-binding fragment thereof specifically recognizes or binds to a protein having the amino acid sequence set forth in SEQ ID NO:2.
  • the antibody or antigen-binding fragment thereof has a Kd value of 10-7-10-10M with a protein having the amino acid sequence shown in SEQ ID NO:2. In some embodiments, the Kd value is 10-7-10-10M , 10-8-10-10M , or 10-9-10-10M . In some embodiments, the antibody or antigen-binding fragment thereof has a Kd value of less than about 10<" 7 >M with a protein having the amino acid sequence set forth in SEQ ID NO:2. In some embodiments, the Kd value is less than about 10-7 M, less than about 10-8 M, less than about 10-9 M, or less than about 10-10 M. In some embodiments, the Kd value is detected by surface plasmon resonance methods.
  • the antigen-binding fragment is selected from F(ab') 2 , Fab', Fab, Fv, scFv, dsFv, or dAb.
  • the antibody or antigen-binding fragment thereof further has a heavy chain constant region and/or a light chain constant region.
  • the heavy chain constant region is derived from murine IgGl or murine IgG2a. In some embodiments, the heavy chain constant region is derived from human IgGl.
  • the antibody or antigen-binding fragment thereof further has a conjugation moiety.
  • the conjugated moiety is a therapeutic agent, a radioisotope, a detectable label, a pharmacokinetic modification moiety, or a purification moiety.
  • the conjugated moieties are attached directly or through a linker, and the conjugated moieties are attached directly or through a linker.
  • the present application also provides an isolated nucleic acid encoding the antibody or antigen-binding fragment thereof that specifically binds to TRPV6 as described in the present application.
  • the nucleic acid comprises the nucleic acid sequence set forth in SEQ ID NO:31 or a nucleic acid sequence having at least 90% sequence identity to SEQ ID NO:31, and the nucleic acid sequence set forth in SEQ ID NO:32 or One or both of the nucleic acid sequences having at least 90% sequence identity to SEQ ID NO:32.
  • the nucleic acid comprises the nucleic acid sequence set forth in SEQ ID NO:33 or a nucleic acid sequence having at least 90% sequence identity to SEQ ID NO:33, and the nucleic acid sequence set forth in SEQ ID NO:34 or One or both of the nucleic acid sequences having at least 90% sequence identity to SEQ ID NO:34.
  • the nucleic acid comprises the nucleic acid sequence set forth in SEQ ID NO:35 or a nucleic acid sequence having at least 90% sequence identity to SEQ ID NO:35, and the nucleic acid sequence set forth in SEQ ID NO:6 or One or both of the nucleic acid sequences having at least 90% sequence identity to SEQ ID NO:6.
  • the present application also provides a vector comprising the nucleic acid sequence described in the present application.
  • the present application also provides a host cell comprising the vector described in the present application.
  • the present application also provides a multispecific antibody comprising the antibody or antigen-binding fragment thereof described herein, and one or more antibodies or antigen-binding portions thereof that specifically bind to other antigens.
  • the present application also provides an antibody conjugate comprising the antibody or antigen-binding fragment thereof described herein or the multispecific antibody described herein.
  • the present application also provides a hybridoma cell line that secretes anti-TRPV6 monoclonal antibody, the hybridoma cell line is 12CT9.5.1, 16CT4.1.1.2 and/or 16CT18.1.1.2, which is preserved in Chinese Type Culture
  • the depository number of 12CT9.5.1 is CCTCC NO: C202119
  • the deposit number of 16CT4.1.1.2 is CCTCC NO: C202124
  • the deposit number of 16CT18.1.1.2 is CCTCC NO: C202125.
  • the application also provides a pharmaceutical composition
  • a pharmaceutical composition comprising the antibody or antigen-binding fragment thereof described in the application, the isolated nucleic acid described in the application, the vector described in the application, and the host described in the application.
  • the present application also provides a reagent for analyzing and detecting TRPV6 in a sample from a subject, the reagent comprising one or more of the antibodies or antigen-binding fragments thereof described herein.
  • the reagents are used to analyze and detect TRPV6 in a sample from a subject.
  • the application also provides a method for detecting TRPV6 in a sample from a subject, the method comprising: (1) contacting the sample with the antibody or antigen-binding fragment described in the application; (2) Optionally, remove unbound antibodies or antibody fragments; (3) detect antibodies or antibody fragments bound to TRPV6 in the sample.
  • step (1) of the method of detecting TRPV6 in a sample from a subject the antibody or antigen-binding fragment described herein is immobilized on a substrate. In some embodiments, in step (1) of the method of detecting TRPV6 in a sample from a subject, the sample is immobilized on a substrate.
  • step (3) of the method for detecting TRPV6 in a sample from a subject, further comprising using a second antibody optionally, the second antibody can directly or indirectly bind to the TRPV6 in the sample, optionally, the epitope of the second antibody is different from the epitope of the antibody or antigen-binding fragment described in this application, optionally, the epitope of the second antibody is different from the epitope of the second antibody described in this application
  • the epitope of the antibody or antigen-binding fragment is the same.
  • the binding of the epitope of the second antibody to TRPV6 is not affected by the antibody or antigen-binding fragment described in this application. Binding of an epitope of an antibody to TRPV6 is affected by the antibody or antigen-binding fragment described herein.
  • step (3) of the method for detecting TRPV6 in a sample from a subject further comprising the use of a second antibody
  • the second antibody can directly or indirectly bind to the present application
  • the antibody or antigen-binding fragment optionally, the second antibody is capable of binding to the constant region portion of the antibody or antigen-binding fragment described herein.
  • the second antibody is coupled to a detection molecule, optionally, the detection molecule includes an enzyme, a fluorescent label, and biotin.
  • the detection molecule is an enzyme, optionally, the enzyme includes horseradish peroxidase, alkaline phosphatase or derivatives thereof.
  • the detection molecule is fluorescein, optionally, the fluorescein includes FITC, Rhodamine, Texas Red, Phycoerythrin or Dylight.
  • the detection molecule is biotin or a derivative thereof.
  • the method of detecting TRPV6 in a sample from a subject further comprises quantifying antibodies that bind to TRPV6 in the sample.
  • the method is immunohistochemistry (IHC), immunofluorescence (IF) enzyme-linked immunosorbent (ELISA) chemiluminescence (CLIA, chemiluminescent immunoassay), immunoturbidimetric (TIA, Turbidimetric inhibition immunoassay) or Western Blot.
  • the method can assess the proportion of cells in the sample that express TRPV6 on the cell surface.
  • the subject in the method of detecting TRPV6 in a sample from a subject, is a human.
  • the application also provides a method for judging the development or risk of developing a disease in a subject, assessing the progression or prognosis of a disease in a subject, or predicting or monitoring the subject in a subject receiving treatment for the disease
  • a method of response to treatment comprising detecting TRPV6 in a sample from a subject by the methods described herein for detecting TRPV6 in a sample from a subject.
  • determining the development or risk of developing a disease in a subject assessing the progression or prognosis of a disease in a subject, or predicting or monitoring the subject's response to treatment in a subject receiving treatment for a disease
  • the method comprises assessing the proportion of cells expressing TRPV6 on the cell surface in the sample, and if the proportion exceeds a predetermined threshold, the experimenter is considered to have the disease or is more likely to benefit from treatment, wherein the threshold is 10%.
  • the treatment is targeted drug therapy.
  • the disease described herein is cancer.
  • the cancer is breast cancer, ovarian cancer, endometrial cancer, bile duct cancer, gastric cancer, esophageal cancer, lung cancer, bowel cancer, pancreatic cancer.
  • the application also provides a kind of test kit
  • the test kit comprises the antibody or its antigen-binding fragment described in the present application, optionally, further comprises for detecting that the antibody or its antigen-binding fragment is combined with TRPV6 Case reagents.
  • kits described herein are used for diagnosing the development or risk of developing a disease in a subject, assessing the progression or prognosis of a disease in a subject, or predicting or monitoring in a subject receiving treatment for a disease the subject's response to treatment.
  • the kits described herein are used for immunohistochemical pathological diagnosis.
  • the kit described in this application is used for immunohistochemical pathological diagnosis of tumor tissue.
  • the disease is cancer, in some embodiments, the cancer is breast cancer, ovarian cancer, endometrial cancer, bile duct cancer, gastric cancer, esophageal cancer, lung cancer, bowel cancer, pancreatic cancer.
  • the present application also provides a method for preparing an antibody that specifically binds TRPV6, the method comprising: (1) coupling the amino acid sequence shown in SEQ ID NO: 3 with a carrier protein to obtain a TRPV6 antigenic peptide (2) using the TRPV6 antigen peptide obtained by step (1) as an immunogen to immunize mice; (3) screening clones through cell fusion and immune peptides to obtain a positive hybridoma cell that efficiently secretes an antibody that specifically binds to TRPV6 (4) Obtain an antibody that specifically binds to TRPV6.
  • the carrier protein is a keyhole limpet hemocyanin (KLH) protein.
  • KLH keyhole limpet hemocyanin
  • a Cys is added to the N-terminus of the amino acid sequence shown in SEQ ID NO: 3, and is coupled to the carrier protein through a free sulfhydryl group.
  • the hybridoma cell lines described herein are mouse hybridoma cell lines 12CT 9.5.1, 16CT 18.1.1.2, and 16CT 4.1.1.2.
  • the application also provides the antibody or antigen-binding fragment thereof described in the application, the isolated nucleic acid described in the application, the vector described in the application, the host cell described in the application, the multispecific described in the application.
  • the present application also provides a method for treating, preventing or diagnosing a disease, the method comprising administering the antibody or antigen-binding fragment thereof of the present application, the multispecificity of the present application to a subject in need thereof Antibodies, antibody conjugates described herein, and pharmaceutical compositions described herein.
  • FIG. 1A shows that CB-Anti-0001 can specifically detect TRPV6 protein in TRPV6 plasmid-transfected 293T cells by immunocytochemistry (left panel), while not in non-TRPV6 plasmid-transfected 293T cells. TRPV6 protein was detected (right panel).
  • Figure 1B shows that CB-Anti-0002 was able to specifically detect TRPV6 protein in TRPV6 plasmid-transfected 293T cells by immunocytochemistry (left panel), but not in non-TRPV6 plasmid-transfected 293T cells TRPV6 protein was detected (right panel).
  • FIG. 1C shows that CB-Anti-0003 was able to specifically detect TRPV6 protein in TRPV6 plasmid-transfected 293T cells by immunocytochemistry (left panel), but not in non-TRPV6 plasmid-transfected 293T cells. TRPV6 protein was detected (right panel).
  • Figure 2A shows the results of immunohistochemical detection of CB-Anti-0001 antibody.
  • Figure 2B shows the results of immunohistochemical detection of CB-Anti-0002 antibody.
  • Figure 2C shows the results of immunohistochemical detection of CB-Anti-0003 antibody.
  • Figure 3 shows the results of IHC comparison experiments of ACC-028 antibody, MABN839 antibody and CB-Anti-0001 antibody against human bladder transitional cell papilloma cells (RT4).
  • Figure 3A shows the IHC results of the ACC-028 antibody
  • Figure 3B shows the IHC results of the MABN839 antibody
  • Figure 3C shows the IHC results of the CB-Anti-0001 antibody. It can be seen that the cell membrane in Figure 3C has a clear and significant staining effect.
  • Figure 4 shows that neither the tissue staining intensity nor the staining ratio of the antibodies stored under different conditions was significantly changed.
  • Fig. 4A is the IHC result of the CB-Anti-0001 antibody stock solution stored at 4°C for 14 days
  • Fig. 4B is the IHC result of the CB-Anti-0001 antibody stock solution kept at 37°C for 14 days
  • Fig. 4C For the IHC results of CB-Anti-0001 antibody working solution stored at 37°C for 14 days.
  • the applicant has submitted the hybridoma cell lines (lines) 12CT9.5.1, 16CT4.1.1.2 and 16CT18.1.1.2 to the China Center for Type Culture Collection for preservation.
  • the deposit number of 12CT9.5.1 is CCTCC NO: C202119
  • the deposit number of 16CT4.1.1.2 is CCTCC NO: C202124
  • the deposit number of 16CT18.1.1.2 is CCTCC NO: C202125
  • the deposit address of the trihybridoma cell line is Wuhan, China University
  • the preservation time is January 13, 2021
  • the preservation unit is the Chinese Type Culture Collection.
  • One aspect of the present application discloses an antibody or antigen-binding fragment thereof that specifically binds TRPV6, wherein the antibody or antigen-binding fragment thereof comprises three heavy chain complementarity determining regions HCDR1 and HCDR2 included in the following heavy chain variable regions and HCDR3: heavy chain variable region shown in SEQ ID NO:25; heavy chain variable region shown in SEQ ID NO:27; or heavy chain variable region shown in SEQ ID NO:29.
  • the antibody or antigen-binding fragment thereof comprises three heavy chain complementarity determining regions HCDR1, HCDR2 and HCDR3 selected from the group consisting of: HCDR1 shown in SEQ ID NO:7, HCDR1 shown in SEQ ID NO:8 HCDR2 shown in SEQ ID NO: 9; HCDR1 shown in SEQ ID NO: 13, HCDR2 shown in SEQ ID NO: 14, HCDR3 shown in SEQ ID NO: 15; or HCDR3 shown in SEQ ID NO: 19 HCDR1 shown in SEQ ID NO: 20, HCDR3 shown in SEQ ID NO: 21.
  • the antibody or antigen-binding fragment thereof of the present application further comprises the antibody or antigen-binding fragment thereof further comprising three light chain complementarity determining regions LCDR1, LCDR2 and LCDR3 included in the light chain variable region as follows: SEQ The light chain variable region shown in ID NO:26; the light chain variable region shown in SEQ ID NO:28; or the light chain variable region shown in SEQ ID NO:30.
  • the antibody or antigen-binding fragment thereof of the present application further comprises three light chain complementarity determining regions LCDR1, LCDR2 and LCDR3 selected from the group consisting of: LCDR1, SEQ ID NO:11 shown in SEQ ID NO:10 LCDR2 shown and LCDR3 shown in SEQ ID NO: 12; LCDR1 shown in SEQ ID NO: 16, LCDR2 shown in SEQ ID NO: 17 and LCDR3 shown in SEQ ID NO: 18; SEQ ID NO: 22 LCDR1 shown, LCDR2 shown in SEQ ID NO: 23, and LCDR3 shown in SEQ ID NO: 24.
  • LCDR1, SEQ ID NO:11 shown in SEQ ID NO:10 LCDR2 shown and LCDR3 shown in SEQ ID NO: 12 LCDR1 shown in SEQ ID NO: 16, LCDR2 shown in SEQ ID NO: 17 and LCDR3 shown in SEQ ID NO: 18
  • SEQ ID NO: 22 LCDR1 shown, LCDR2 shown in SEQ ID NO: 23, and LCDR3 shown in SEQ ID NO: 24.
  • the antibody or antigen-binding fragment thereof of the present application comprises HCDR1 shown in SEQ ID NO:7, HCDR2 shown in SEQ ID NO:8, HCDR3 shown in SEQ ID NO:9, SEQ ID NO: LCDR1 shown in 10, LCDR2 shown in SEQ ID NO: 11, and LCDR3 shown in SEQ ID NO: 12.
  • the antibody or antigen-binding fragment thereof of the present application comprises HCDR1 shown in SEQ ID NO: 13, HCDR2 shown in SEQ ID NO: 14, HCDR3 shown in SEQ ID NO: 15, SEQ ID NO: LCDR1 shown in 16, LCDR2 shown in SEQ ID NO: 17 and LCDR3 shown in SEQ ID NO: 18.
  • the antibody or antigen-binding fragment thereof of the present application comprises HCDR1 shown in SEQ ID NO: 19, HCDR2 shown in SEQ ID NO: 20, HCDR3 shown in SEQ ID NO: 21, SEQ ID NO: LCDR1 shown in 22, LCDR2 shown in SEQ ID NO: 23 and LCDR3 shown in SEQ ID NO: 24.
  • the antibody or antigen-binding fragment thereof of the present application comprises a heavy chain variable region VH selected from the group consisting of: the heavy chain variable region shown in SEQ ID NO: 25; the heavy chain variable region shown in SEQ ID NO: 27 The heavy chain variable region shown; or the heavy chain variable region shown in SEQ ID NO:29.
  • the antibody or antigen-binding fragment thereof further comprises a light chain variable region VL selected from the group consisting of: a light chain variable region shown in SEQ ID NO:26; a light chain variable region shown in SEQ ID NO:28 The light chain variable region of ; or the light chain variable region shown in SEQ ID NO: 30.
  • the antibody or antigen-binding fragment thereof of the present application comprises a heavy chain variable region set forth in SEQ ID NO:25 and a light chain variable region set forth in SEQ ID NO:26. In some embodiments, the antibody or antigen-binding fragment thereof of the present application comprises a heavy chain variable region set forth in SEQ ID NO:27 and a light chain variable region set forth in SEQ ID NO:28. In some embodiments, the antibody or antigen-binding fragment thereof of the present application comprises a heavy chain variable region set forth in SEQ ID NO:29 and a light chain variable region set forth in SEQ ID NO:30.
  • antibody as used herein includes any immunoglobulin, monoclonal, multivalent, multispecific or bispecific (bivalent) antibody.
  • a native intact antibody contains two heavy chains and two light chains bound to each other by disulfide chains.
  • Each heavy chain of an antibody consists of a variable region ( VH ) and first, second and third constant regions ( CH1 , CH2 , CH3 , respectively), while each light chain of an antibody consists of a variable region.
  • VL variable region
  • CL constant region
  • variable regions in each chain are roughly subdivided into 3 hypervariable regions, called complementarity determining regions (CDRs) (wherein light chain CDRs include LCDR1, LCDR2, LCDR3. Heavy chain CDRs include HCDR1, HCDR2, HCDR3).
  • CDRs complementarity determining regions
  • an "antigen-binding fragment" of an antibody, an “antigen-binding portion” of an antibody, and the like, as used herein, includes any naturally occurring, enzymatically obtainable, synthetic or genetically engineered polypeptide that specifically binds an antigen to form a complex thing.
  • Antigen-binding fragments of antibodies can, for example, be derived from intact antibody molecules using any suitable standard technique, such as proteolytic digestion or involving manipulation and expression encoding antibody variable domains and optionally constant Recombinant genetic engineering of DNA domains.
  • DNA can be sequenced and manipulated chemically or by using molecular biology techniques to, for example, arrange one or more variable and/or constant domains into a suitable configuration, or introduce codons, to generate cysteines residues, modified, added or deleted amino acids, etc.
  • Non-limiting examples of antigen-binding fragments include: (i) Fab fragments; (ii) F(ab')2 fragments; (iii) Fd fragments; (iv) Fv fragments; (v) single-chain Fv (scFv) molecules; (vi) dAb fragments; and (vii) minimal recognition units that mimic the amino acid residues of the hypervariable regions of antibodies (eg, isolated complementarity determining regions (CDRs) such as CDR3 peptides) or FR3-CDR3-FR4 peptides.
  • CDRs complementarity determining regions
  • engineered molecules such as domain-specific antibodies, single-domain antibodies, domain-deleted antibodies, chimeric antibodies, CDR-grafted antibodies, diabodies, tribodies, tetrabodies, minibodies, nanobodies (e.g., monovalent nanobodies, di- Nanobodies, etc.), small modular immunopharmaceuticals (SMIPs), and shark variant IgNAR domains are also included within the expression "antigen-binding fragment" as used herein.
  • SMIPs small modular immunopharmaceuticals
  • the CDR boundaries of the antibodies and antigen-binding fragments disclosed in this application can be named or identified by Kabat, Chothia or Al-Lazikani nomenclature.
  • the CDR boundaries of the antibody are determined according to the Kabat database.
  • the three CDRs are separated by flanking contiguous portions called framework regions (FRs, where heavy chain FRs include HFR1, HFR2, HFR3, and HFR4, and light chain FRs include LFR1, LFR2, LFR3, and LFR4), which are more highly than CDRs is conserved and forms a scaffold supporting the hypervariable loop.
  • FRs framework regions
  • VH and VL each comprise 3 CDRs and 4 FRs (human amino acid residues N-terminal to C-terminal) in the following order: FRl, CDRl, FR2, CDR2, FR3, CDR3, FR4.
  • the constant regions of the heavy and light chains are not involved in antigen binding, but exhibit a variety of effector functions.
  • Mammalian heavy chains are classified as ⁇ , ⁇ , ⁇ , ⁇ , and ⁇ , and mammalian light chains are classified as ⁇ or ⁇ .
  • Antibodies can be divided into 5 major classes: IgA, IgD, IgE, IgG and IgM according to the amino acid sequence of their heavy chain constant region and the presence or absence of ⁇ , ⁇ , ⁇ , ⁇ and ⁇ , respectively. Subclasses of several major antibody classes such as IgG1 ( ⁇ 1 heavy chain), IgG2 ( ⁇ 2 heavy chain), IgG3 ( ⁇ 3 heavy chain), IgG4 ( ⁇ 4 heavy chain), IgA1 ( ⁇ 1 heavy chain) or IgA2 ( ⁇ 2 heavy chain) ).
  • the antibody or antigen-binding fragment thereof of the present application specifically recognizes or binds to a protein having the amino acid sequence shown in SEQ ID NO:2.
  • the Kd value of the antibody or antigen-binding fragment thereof of the present application and the protein having the amino acid sequence shown in SEQ ID NO: 2 is 10 -7 -10 -10 M. In some embodiments, the Kd value is 10-7-10-10M , 10-8-10-10M , or 10-9-10-10M . In some embodiments, the antibody or antigen-binding fragment thereof has a Kd value of less than about 10<" 7 >M with a protein having the amino acid sequence set forth in SEQ ID NO:2. In some embodiments, the Kd value is less than about 10-7 M, less than about 10-8 M, less than about 10-9 M, or less than about 10-10 M. In some embodiments, the Kd value is detected by surface plasmon resonance methods.
  • the antigen-binding fragment of the present application is selected from F(ab') 2 , Fab', Fab, Fv, scFv, dsFv, or dAb.
  • the antibody or antigen-binding fragment thereof of the present application further has a heavy chain constant region and/or a light chain constant region.
  • the heavy chain constant region is derived from murine IgGl or murine IgG2a. In some embodiments, the heavy chain constant region is derived from human IgGl.
  • the antibody or antigen-binding fragment thereof of the present application further has a conjugation moiety.
  • the conjugated moiety is a therapeutic agent, a radioisotope, a detectable label, a pharmacokinetic modification moiety, or a purification moiety.
  • the conjugated moieties are attached directly or via linkers.
  • therapeutic agent can be any pharmaceutical compound used to treat or prevent a disease in a subject, including small molecules with a molecular weight of less than 500, nucleotides (eg, DNA, plasmid DNA, RNA, siRNA ) , antisense oligonucleotides, aptamers, etc.), short peptides, proteins (eg, enzymes).
  • nucleotides eg, DNA, plasmid DNA, RNA, siRNA
  • antisense oligonucleotides eg., antisense oligonucleotides, aptamers, etc.
  • short peptides eg, proteins
  • the radioisotope may be selected from the group consisting of 3 H, 11 C, 14 C, 18 F, 32 P, 33 P, 35 S, 45 Ti, 47 Sc, 52 Fe, 59 Fe, 62 Cu, 64 Cu, 67 Cu, 67 Ga, 68 Ga, 75 Sc, 77 As, 86 Y, 89 Sr, 89 Zr, 90 Y, 90 Nb, 94 Tc, 99 Tc, 99 Mo, 105 Pd, 105 Rh, 111 Ag , 111 In, 123 I, 124 I, 125 I, 131 I, 133 Xe, 142 Pr, 143 Pr, 149 Pm, 153 Sm, 154 Gd, 155 Gd, 156 Gd, 157 Gd, 158 Gd, 161 Tb, 166 Dy, 169 Er, 175 Lu, 177 Lu, 186 Re, 188 Re, 189 Re, 194 Ir, 198 Au, 199 Au, 211 At, 211 Pb, 212
  • detectable label can be any detection molecule that is conjugated, directly or indirectly, to an antibody of the invention, while being suitable for or contributing to the detection of the level of TRPV6.
  • the detection molecules include enzymes, fluorescent labels, and biotin.
  • the enzymes include peroxidase (eg, horseradish peroxidase), alkaline phosphatase, beta-galactosidase, glucoamylase, sugar oxidase, urease, heterocyclic oxidase (eg, yellow oxidase). purine oxidase), malate dehydrogenase or their derivatives.
  • the fluorescent marker can be fluorescein, optionally, the fluorescein includes fluorescein isothiocyanate (FITC), rhodamine, Texas red, phycoerythrin, green fluorescent protein (GFP), Dylight , Cy3 or Cy5.
  • FITC fluorescein isothiocyanate
  • rhodamine rhodamine
  • Texas red rhodamine
  • GFP green fluorescent protein
  • Dylight Cy3 or Cy5.
  • the present application also discloses an isolated nucleic acid encoding the antibody or antigen-binding fragment thereof that specifically binds to TRPV6 as described in the present application.
  • the nucleic acid comprises the nucleic acid sequence set forth in SEQ ID NO:31 or a nucleic acid sequence having at least 90% sequence identity to SEQ ID NO:31, and the nucleic acid sequence set forth in SEQ ID NO:32 or One or both of the nucleic acid sequences having at least 90% sequence identity to SEQ ID NO:32.
  • the nucleic acid comprises the nucleic acid sequence set forth in SEQ ID NO:33 or a nucleic acid sequence having at least 90% sequence identity to SEQ ID NO:33, and the nucleic acid sequence set forth in SEQ ID NO:34 or One or both of the nucleic acid sequences having at least 90% sequence identity to SEQ ID NO:34.
  • the nucleic acid comprises the nucleic acid sequence set forth in SEQ ID NO:35 or a nucleic acid sequence having at least 90% sequence identity to SEQ ID NO:35, and the nucleic acid sequence set forth in SEQ ID NO:6 or One or both of the nucleic acid sequences having at least 90% sequence identity to SEQ ID NO:6.
  • the present application also discloses a vector comprising the nucleic acid sequence described in the present application.
  • the present application also discloses a host cell comprising the vector described in the present application.
  • the present application also discloses a multispecific antibody comprising the antibody or antigen-binding fragment thereof described herein, and one or more antibodies or antigen-binding portions thereof that specifically bind to other antigens.
  • the present application also discloses an antibody conjugate, which comprises the antibody or antigen-binding fragment thereof described in the present application or the multispecific antibody described in the present application.
  • the present application also discloses a hybridoma cell line that secretes anti-TRPV6 monoclonal antibody, and the hybridoma cell line is 12CT9.5.1, 16CT4.1.1.2 and/or 16CT18.1.1.2, which are deposited in China Typical Culture Collection Center, wherein the deposit number of 12CT9.5.1 is CCTCC NO: C202119, the deposit number of 16CT4.1.1.2 is CCTCC NO: C202124, and the deposit number of 16CT18.1.1.2 is CCTCC NO: C202125.
  • the present application also discloses a pharmaceutical composition
  • a pharmaceutical composition comprising the antibody or antigen-binding fragment thereof described in the present application, the isolated nucleic acid described in the present application, the carrier described in the present application, the A host cell, a multispecific antibody described herein or an antibody conjugate described herein, and a pharmaceutically acceptable carrier.
  • pharmaceutically acceptable means that, within the scope of sound medical judgment, it is suitable for use in contact with cells of humans and other animals without undue toxicity, irritation, allergic response, etc., and It is commensurate with a reasonable benefit/risk ratio.
  • pharmaceutically acceptable carrier refers to a subject used to deliver an antibody or antigen-binding fragment thereof, isolated nucleic acid, vector, host cell, multispecific antibody or antibody provided herein to a subject
  • a pharmaceutically acceptable solvent, suspension or any other pharmaceutically inert carrier for the conjugate that does not interfere with the antibody or antigen-binding fragment thereof, isolated nucleic acid, vector, host cell, multispecific antibody or antibody conjugate The structure, morphology and properties of associations.
  • Certain such carriers are capable of formulating the antibody or antigen-binding fragment thereof, isolated nucleic acid, vector, host cell, multispecific antibody or antibody conjugate, for example, as tablets, pills, capsules, liquids, gels, syrups Tablets, slurries, suspensions and pastilles for oral ingestion by subjects.
  • Certain such vectors enable the antibody or antigen-binding fragment thereof, isolated nucleic acid, vector, host cell, multispecific antibody or antibody conjugate to be formulated for injection, infusion or topical administration.
  • Pharmaceutically acceptable carriers used in the pharmaceutical compositions provided herein include, but are not limited to, for example, pharmaceutically acceptable liquid, gel or solid carriers, aqueous carriers (for example, Sodium Chloride Injection, Ringer's Injection, Isotonic Dextrose Injection, Sterile Water Injection, or Dextrose and Lactated Ringer's Injection), non-aqueous vehicles (e.g., fixed oils of vegetable origin, cottonseed oil, corn oil, sesame oil or peanut oil), antimicrobials, isotonic agents (eg, sodium chloride or dextrose), buffers (eg, phosphoric acid or citric acid buffers), antioxidants (eg, sodium bisulfate), anesthetics (eg, , procaine hydrochloride), suspending/dispersing agents (eg, sodium carboxymethylcellulose, hydroxypropylmethylcellulose, or polyvinylpyrrolidone), chelating agents (eg, EDTA (ethylenediaminetetraacetic acid)
  • the pharmaceutical composition is an injectable formulation.
  • Injectable preparations include sterile aqueous solutions or dispersions, suspensions or emulsions. In all cases, preparations for injection should be sterile and should be fluid to facilitate injection. Injectable preparations should be stable under the conditions of manufacture and storage and must be protected from contamination by microorganisms such as bacteria and fungi.
  • the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and/or vegetable oils. Injectable preparations should maintain proper fluidity.
  • Proper fluidity can be maintained, for example, by the use of coatings such as lecithin, by the use of surfactants, and the like.
  • Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, such as parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like.
  • the pharmaceutical composition is an oral formulation.
  • Oral formulations include, but are not limited to, capsules, cachets, pills, tablets, lozenges (using a flavored base, usually sucrose and acacia or tragacanth), powders, granules, or solutions in aqueous or non-aqueous liquids formulations or suspensions, or as oil-in-water or water-in-oil liquid emulsions, or as elixirs or syrups, or as pastilles (using inert bases such as gelatin and glycerol, or sucrose and acacia) and/or as Mouthwash, etc.
  • the antibodies or antigen-binding fragments thereof In solid dosage forms (eg, capsules, tablets, pills, dragees, powders, granules, etc.) for oral administration, the antibodies or antigen-binding fragments thereof, isolated nucleic acids, vectors, host cells, multispecific antibodies Or antibody conjugates mixed with one or more pharmaceutically acceptable carriers, such as sodium citrate or dicalcium hydrogen phosphate, and/or any one of the following: (1) fillers or bulking agents , for example, starch, lactose, sucrose, glucose, mannitol and/or silicic acid; (2) binders, for example, carboxymethyl cellulose, alginate, gelatin, polyvinylpyrrolidone, sucrose and/or acacia; (3) humectants, such as glycerin; (4) disintegrants, such as agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates and sodium carbonate; (5) solution blockers, such as
  • the antibody or antigen-binding fragment thereof, isolated nucleic acid, vector, host cell, multispecific antibody or antibody conjugate is mixed with any of the following: a pharmaceutically acceptable of emulsions, microemulsions, solutions, suspensions, syrups and elixirs.
  • liquid dosage forms may contain inert diluents commonly used in the art, for example, water or other solvents, solubilizers and Emulsifiers, for example, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, isopropanol, 1,3-butanediol, oils (especially, cottonseed oil, peanut oil, corn oil, olive oil, castor oil and sesame oil), glycerin, tetrahydrofurfuryl alcohol, polyethylene glycol and sorbitan fatty acid esters and mixtures thereof.
  • the oral compositions can also contain adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming and preservitol, sorbitan fatty acid esters and mixtures thereof.
  • adjuvants such as wetting agents, emulsifying and suspending agents, sweeten
  • the pharmaceutical composition is an oral spray formulation or a nasal spray formulation.
  • Spray formulations include, but are not limited to, aqueous aerosols, non-aqueous suspensions, liposome formulations or solid particle formulations, and the like.
  • Aqueous aerosols are prepared by mixing an aqueous solution or suspension of the agent with conventional pharmaceutically acceptable carriers and stabilizers. Carriers and stabilizers vary according to the requirements of the particular pharmaceutical ingredient, but in general they include nonionic surfactants (Tween or polyethylene glycol), oleic acid, lecithin, amino acids, eg, glycine, buffer solutions , salt, sugar or sugar alcohol. Aerosols are usually prepared from isotonic solutions and can be delivered by spray.
  • the pharmaceutical composition may be administered in admixture with one or more other drugs.
  • the pharmaceutical composition comprises at least one other drug.
  • the other drugs are antineoplastics, cardiovascular drugs, anti-inflammatory drugs, antiviral drugs, digestive system drugs, nervous system drugs, respiratory system drugs, immune system drugs, dermatological drugs, metabolic drugs, and the like.
  • the pharmaceutical composition can be administered to a subject in need thereof by a suitable route, including but not limited to oral, injection (eg, intravenous, intramuscular, subcutaneous, intradermal, intracardiac, intrathecal, intrapleural, intraperitoneal injection, etc.), mucosal (eg, intranasal, intraoral administration, etc.), sublingual, rectal, transdermal, intraocular, and pulmonary administration.
  • a suitable route including but not limited to oral, injection (eg, intravenous, intramuscular, subcutaneous, intradermal, intracardiac, intrathecal, intrapleural, intraperitoneal injection, etc.), mucosal (eg, intranasal, intraoral administration, etc.), sublingual, rectal, transdermal, intraocular, and pulmonary administration.
  • the pharmaceutical composition can be administered intravenously, subcutaneously, orally, intramuscularly, or intraventricularly.
  • the present application also discloses a reagent for analyzing and detecting TRPV6 in a sample from a subject, the reagent comprising one or more of the antibodies or antigen-binding fragments thereof described herein.
  • the reagents are used to analyze and detect TRPV6 in a sample from a subject.
  • the present application also discloses a method for detecting TRPV6 in a sample from a subject, the method comprising: (1) contacting the sample with the antibody or antigen-binding fragment described in the present application; (2) ) optionally, removing unbound antibodies or antibody fragments; (3) detecting antibodies or antibody fragments bound to TRPV6 in the sample.
  • detecting can be by determining and measuring the presence or absence of a molecule (eg, a polypeptide, protein, or nucleic acid molecule), or by determining and measuring an interaction between molecules (eg, binding, agonizing or antagonism, etc.), such as protein-protein interactions (eg, between an antibody and an antigen), protein-nucleic acid interactions, or nucleic acid-nucleic acid interactions.
  • a molecule eg, a polypeptide, protein, or nucleic acid molecule
  • an interaction between molecules eg, binding, agonizing or antagonism, etc.
  • protein-protein interactions eg, between an antibody and an antigen
  • protein-nucleic acid interactions eg, between an antibody and an antigen
  • nucleic acid-nucleic acid interactions e.g, antigen, protein-nucleic acid interactions.
  • detection is by determining and measuring the signal of a detection molecule conjugated directly or indirectly to the antibody. Detection can be
  • detection is performed using immunohistochemistry (IHC), enzyme-linked immunosorbent assay (ELISA), immunofluorescence (IF), chemiluminescence (CLIA), immunoturbidimetry (TIA), or western blotting (WesternBlot).
  • IHC immunohistochemistry
  • ELISA enzyme-linked immunosorbent assay
  • IF immunofluorescence
  • CLIA chemiluminescence
  • TIA immunoturbidimetry
  • WesternBlot western blotting
  • step (1) of the method of detecting TRPV6 in a sample from a subject the antibody or antigen-binding fragment described herein is immobilized on a substrate.
  • the sample in step (1) of the method of detecting TRPV6 in a sample from a subject, is immobilized on a substrate.
  • the sample is a cell or tissue. Samples include, but are not limited to, cytocentrifugation preparations, cytology smears, core biopsies, fine needle aspiration, and/or tissue sections (eg, cryostat tissue sections, paraffin-embedded tissue sections).
  • the sample comprises living cells.
  • the sample comprises tumor cells.
  • the immobilization is performed using a chemical fixative.
  • Histological samples can be prepared using cross-linking fixatives, such as aldehydes, including, for example, formaldehyde, paraformaldehyde, and glutaraldehyde.
  • Tissue samples can be fixed with formaldehyde and embedded in paraffin. It can also be fixed with paraformaldehyde, embedded in temperature-sensitive cryogenic materials, and snap-frozen with liquid nitrogen.
  • Other classes of chemical fixatives include oxidizing agents and alcohol fixatives. It can also be fixed by physical methods.
  • step (3) of the method for detecting TRPV6 in a sample from a subject, further comprising using a second antibody optionally, the second antibody can directly or indirectly bind to the TRPV6 in the sample, optionally, the epitope of the second antibody is different from the epitope of the antibody or antigen-binding fragment described in this application, optionally, the epitope of the second antibody is different from the epitope of the second antibody described in this application
  • the epitope of the antibody or antigen-binding fragment is the same.
  • the binding of the epitope of the second antibody to TRPV6 is not affected by the antibody or antigen-binding fragment described in this application. Binding of an epitope of an antibody to TRPV6 is affected by the antibody or antigen-binding fragment described herein.
  • epitope refers to an antigenic determinant that interacts with a specific antigen-binding site (called a paratope) in the variable region of an antibody molecule.
  • a single antigen can have more than one epitope.
  • different antibodies can bind to different regions on an antigen and can have different biological effects.
  • the epitope can be a conformational epitope or a linear epitope. Conformational epitopes are created by the spatial juxtaposition of amino acids from different segments of a linear polypeptide chain. Linear epitopes are epitopes that arise from adjacent amino acid residues in a polypeptide chain. In certain instances, epitopes may comprise sugar, phosphoryl, or sulfonyl moieties on the antigen.
  • step (3) of the method for detecting TRPV6 in a sample from a subject further comprising the use of a second antibody
  • the second antibody can directly or indirectly bind to the present application
  • the antibody or antigen-binding fragment optionally, the second antibody is capable of binding to the constant region portion of the antibody or antigen-binding fragment described herein.
  • Secondary antibody as used herein is intended to better detect anti-TRPV6 antibodies, and secondary antibodies are generally commercially available.
  • the second antibody described in this application is coupled to a detection molecule, optionally, the detection molecule includes an enzyme, a fluorescent label and biotin.
  • the detection molecule is an enzyme, optionally, the enzyme includes peroxidase (eg, horseradish peroxidase), alkaline phosphatase, beta-galactosidase, glucoamylase , sugar oxidase, urease, heterocycle oxidase (eg, xanthine oxidase), malate dehydrogenase or derivatives thereof.
  • the detection molecule is fluorescein, optionally, the fluorescein includes FITC, Rhodamine, Texas Red, Phycoerythrin, GFP, Cy3, Cy5 or Dylight.
  • the detection molecule is biotin or a derivative thereof.
  • the method of detecting TRPV6 in a sample from a subject further comprises quantifying antibodies that bind to TRPV6 in the sample.
  • the method is immunohistochemistry (IHC), enzyme-linked immunosorbent assay (ELISA), immunofluorescence (IF), chemiluminescence (CLIA), immunoturbidimetry (TIA), or Western Blot .
  • the method can assess the proportion of cells in the sample that express TRPV6 on the cell surface.
  • the subject in the method of detecting TRPV6 in a sample from a subject, is a human.
  • the application also discloses a method for judging the development or risk of developing a disease in a subject, assessing the progression or prognosis of a disease in a subject, or predicting or monitoring the subject in a subject undergoing treatment for the disease.
  • a method of a subject's response to treatment comprising detecting TRPV6 in a sample from a subject by the methods described herein for detecting TRPV6 in a sample from a subject.
  • determining the development or risk of developing a disease in a subject assessing the progression or prognosis of a disease in a subject, or predicting or monitoring the subject's response to treatment in a subject receiving treatment for a disease
  • the method comprises assessing the proportion of cells expressing TRPV6 on the cell surface in the sample, and if the proportion exceeds a predetermined threshold, the experimenter is considered to have the disease or is more likely to benefit from treatment, wherein the threshold is 10%.
  • the treatment is targeted drug therapy.
  • the terms “benefit”, “benefit” or “beneficial” as used in this application refer to any desired effect, including but not limited to: (1) inhibiting (eg, reducing, slowing, or completely halting) the disease to some extent; progression, including slowing and complete arrest; (2) reducing the number of disease episodes and/or symptoms; (3) reducing lesion size; (4) inhibiting the infiltration of disease cells into adjacent surrounding organs and/or tissues; (5) ) inhibition of disease spread; (6) some relief of one or more symptoms associated with the disease; (7) increased time to disease-free after treatment; (8) decreased autoimmune responses, which may but not necessarily lead to Regression or ablation of disease lesions, eg, progression-free survival; (9) increased overall survival; (10) higher response rates; and/or (11) decreased mortality at a given time point after treatment.
  • predicting or monitoring the subject's response to treatment involves assessing whether the subject's tumor is reduced or worsened. In some embodiments, predicting or monitoring the subject's response to treatment may involve assessing whether and/or the likelihood that the subject will get better after receiving treatment (eg, treatment with a particular drug).
  • the predictive or supervised methods of the present application can be used to make treatment decisions clinically. Following administration of a treatment regimen (eg, a given treatment regimen, including, for example, administration of a given therapeutic drug or combination, surgical intervention, etc.), the methods of prediction or surveillance of the present application are useful in evaluating whether a particular subject will survive long-term. Possibly a valuable tool.
  • the disease described herein is cancer.
  • the cancer is breast cancer, ovarian cancer, endometrial cancer, bile duct cancer, gastric cancer, esophageal cancer, lung cancer, bowel cancer, pancreatic cancer.
  • the cancer is HER2 + breast cancer, triple negative breast cancer, or colorectal cancer.
  • the present application also discloses a kit, which comprises the antibody or its antigen-binding fragment described in the present application, and optionally, further includes a kit for detecting the relationship between the antibody or its antigen-binding fragment and TRPV6 Binding reagents.
  • kits described herein are used for diagnosing the development or risk of developing a disease in a subject, assessing the progression or prognosis of a disease in a subject, or predicting or monitoring in a subject receiving treatment for a disease the subject's response to treatment.
  • the kits described herein are used for immunohistochemical pathological diagnosis.
  • the kit described in this application is used for immunohistochemical pathological diagnosis of tumor tissue.
  • the disease is cancer, in some embodiments, the cancer is breast cancer, ovarian cancer, endometrial cancer, bile duct cancer, gastric cancer, esophageal cancer, lung cancer, bowel cancer, pancreatic cancer. In yet other embodiments, the cancer is HER2+ breast cancer, triple negative breast cancer, or colorectal cancer.
  • the present application also discloses a method for preparing an antibody that specifically binds TRPV6, the method comprising: (1) coupling the amino acid sequence shown in SEQ ID NO: 3 with a carrier protein to obtain TRPV6 antigen (2) using the TRPV6 antigen peptide obtained in step (1) as an immunogen to immunize mice; (3) screening clones through cell fusion and immune peptides to obtain a positive hybridoma that efficiently secretes an antibody that specifically binds to TRPV6 cell line; (4) obtaining an antibody that specifically binds to TRPV6.
  • the carrier protein is a keyhole limpet hemocyanin (KLH) protein.
  • KLH keyhole limpet hemocyanin
  • a Cys is added to the N-terminus of the amino acid sequence shown in SEQ ID NO: 3, and is coupled to the carrier protein through a free sulfhydryl group.
  • SEQ ID NO: 3 PLKPRTNNRTSPRDNTLLQQKLLQEAYMTPK.
  • the hybridoma cell lines described herein are mouse hybridoma cell lines 12CT 9.5.1, 16CT 18.1.1 or 16CT 4.1.1.2.
  • the antibody produced by cell line 12CT 9.5.1 includes CB-Anti-0001 antibody
  • the antibody produced by cell line 16CT4.1.1.2 includes CB-Anti-0002 antibody
  • the antibody produced by cell line 16CT18.1.1 includes CB-Anti- 0003 antibody.
  • the present application also discloses the use of the antibody or antigen-binding fragment thereof, the multispecific antibody described in the present application, the antibody conjugate described in the present application, and the pharmaceutical composition described in the present application. Use in a medicament for the treatment and/or prevention and/or diagnosis of TRPV6-related diseases.
  • the present application also discloses a method for treating, preventing or diagnosing a disease, the method comprising administering to a subject in need thereof the antibody or antigen-binding fragment thereof, the multispecific Antibodies, antibody conjugates described herein, and pharmaceutical compositions described herein.
  • the cross-linked polypeptide in Example 1 was emulsified with Freund's complete adjuvant, and 4 to 6-week-old female Balb/c mice (purchased from Beijing Weitong Lihua Laboratory Animal Technology Co., Ltd.) were immunized and injected subcutaneously in the abdomen. Mice 6 points, the dose is 60 ⁇ g/mice.
  • the immunization was boosted once every 14 days, and the antigen was emulsified with Freund's incomplete adjuvant at a dose of 30 ⁇ g/only.
  • indirect ELISA (wavelength 450nm) was used to detect the polyclonal antibody titer against the immunogen in the serum of the mice.
  • the mice with the highest titer were immunized by tail vein injection, and the antigen was mixed with normal saline. The dose is 50 ⁇ g/only.
  • a suspension of mouse spleen cells that reached the immune target was prepared, mixed with mouse myeloma cells F0 at a ratio of 5:1, and centrifuged at 1500 rpm for 5 minutes. After discarding the supernatant, the centrifuge tube was placed in a 37° C. water bath, and 1 mL of PEG1500 (Roche) was slowly added within 1 minute, and the cells were agitated. After standing in warm water for 1 minute, 10 mL of serum-free IMDM (Sigma) was added, mixed well, and centrifuged at 1000 rpm for 5 minutes.
  • the size and density of the cloned cell clusters are moderate. Under the dissecting microscope, the round, solid and large clone clusters are drawn into the 96-well culture plate prepared with the medium in advance, and put into 37°C, 5% CO 2 . Cultivated in an incubator.
  • the cells After 3 days, the cells accounted for about 2/3 of the bottom area, and 100 ⁇ L of the supernatant was taken for ELISA screening with immunogens and synthetic polypeptides respectively. Positive clones were completely exchanged, and 200 ⁇ L of complete medium containing feeder cells and 1% HT (Sigma) was added. The second ELISA screening was performed two days later, and the positive clones were transferred to 24-well plates prepared with medium (containing feeder cells and HT). Five days later, 100 ⁇ L of supernatant was taken for the third ELISA screening, and three positive clones with higher titers, 12CT 9.5.1, 16CT 18.1.1.2 and 16CT 4.1.1.2, were screened and transferred to 6-well plates and cell culture. Flasks were expanded and frozen.
  • Log phase cells were washed with serum-free medium and suspended, counted at ⁇ 5x105 /mL, and 1 mL of the suspended cells were injected intraperitoneally into mice previously sensitized with paraffin oil. Collection of ascites was started 7 days later. The removed ascites was centrifuged at 4000 rpm for 10 minutes at 4°C. Carefully aspirate the ascites in the middle, collect it in a centrifuge tube, and store it at 4°C or -20°C.
  • Antibodies were purified from ascites by Protein G (GE) affinity chromatography according to the manufacturer's instructions. The purity was identified by SDS-PAGE gel, and the concentration was determined by Bradford method. Purified antibodies were stored at -20°C.
  • GE Protein G
  • the obtained anti-TRPV6 antibody was immobilized on the SPR chip, and then the immune peptide was diluted to 11.52nM with 1 ⁇ PBST as a diluent, and then diluted 1.3 times, and the final concentration was 4.04nM, a total of 5 concentration gradients.
  • the SPR instrument was used for affinity detection, and the affinity constant of CB-Anti-0001 was calculated to be 5.19x10 -10 after automatic analysis by the instrument.
  • 293T cells transfected with TRPV6 protein were selected, and the recognition specificity of the monoclonal antibody of the present invention was detected by immunocytochemical method.
  • the immunocytochemical experiment process was as follows: TRPV6 plasmid was transfected in 293T cells, and the transfected cells were plated on In a 24-well plate containing slides, cells were cultured in IMDM+10% FBS medium for 72 hours, the supernatant was removed, washed once with PBS, fixed with methanol for 30 seconds, and washed twice with PBS.
  • CB-Anti-0001 antibody, CB-Anti-0002 antibody and CB-Anti-0003 antibody were able to specifically detect TRPV6 protein by immunocytochemistry in 293T cells transfected with TRPV6 plasmid, respectively , while no TRPV6 protein was shown to be detected in 293T cells that were not transfected with TRPV6 plasmid. This result indicates that the obtained anti-TRPV6 antibody can specifically recognize the TRPV6 protein, that is, it has the recognition property.
  • variable region sequence of the antibody heavy chain and light chain Take the cultured hybridoma cell line 1 ⁇ 10 6 , centrifuge to get the supernatant, and entrust the cell pellet to Suzhou Jinweizhi Biotechnology Co., Ltd. to determine the variable region sequence of the antibody heavy chain and light chain.
  • the following shows an exemplary antibody heavy chain variable region Region sequences and antibody light chain variable region sequences.
  • tissue wax blocks were serially sectioned, with a thickness of 5 ⁇ m.
  • the serial sections were unfolded in warm water at 45°C, mounted on a positron-resistant slide, and air-dried at room temperature overnight, then placed in -20°C. Long-term preservation.
  • CB-Anti-0001 antibody, CB-Anti-0002 antibody and CB-Anti-0003 antibody were able to detect TRPV6 protein in tissue sections by immunohistochemistry, respectively.
  • the inventors also recorded the staining of tumor cell membranes by using the H-score scoring method.
  • An H-score of more than 60 was recorded as strong staining, and an H-score of 1-60 was recorded as weak staining, strong staining and weak staining.
  • the total staining was positive; the H-score of 0 was recorded as negative.
  • the levels of TRPV6 in each tumor tissue detected by IHC were counted, and the TRPV6 mRNA levels in the TCGA database were compared and verified to evaluate the specificity of the antibody. The recorded information is listed in Table 4.
  • the results show that using the antibody of the present invention to detect the TRPV6 protein level, the cancer species with a higher positive rate (especially a higher proportion of strong staining) are correspondingly counted in the Cancer Genome Atlas Program (the Cancer Genome Atlas Program, that is, the TCGA database). TRPV6 mRNA levels were also higher (eg, TPM greater than 1). It can be seen that the use of the antibody of the present invention can accurately evaluate the expression of TRPV6 on the cell surface, and then determine whether the detected sample is a cancer cell expressing TRPV6.
  • Table 4 The level of TRPV6 in tumor tissue detected by IHC
  • Embodiment 7 IHC comparative experiment
  • Anti-Human TRPV6 (extracellular) Antibody (Item No. ACC-028, purchased from Alomone Labs, RRID: AB_2756545, referred to herein as "ACC-028 antibody”)
  • antibody “Anti-TrpV6 Antibody, clone 4A5.1” (Cat. No. MABN839, purchased from Sigma-Aldrich Company, referred to herein as "MABN839 antibody”
  • MABN839 antibody CB-Anti-0001 antibody for comparative experiments.
  • CDX tumor model RT4 human bladder transitional cell papilloma cells
  • Hematoxylin was counterstained for 25 seconds, and PBS was back to blue for 30 seconds.
  • the results showed that the detection sensitivity of ACC-028 antibody was low, and specific signals were only detected on a small amount of RT4 cell membranes (see Figure 3A); the specificity of MABN839 antibody was poor, and signals were detected in all tissue cells and interstitial cells ( See FIG. 3B ); in contrast, the CB-Anti-0001 antibody has accurate and clear signal localization, good specificity and high sensitivity (see FIG. 3C ), and is an ideal antibody for IHC application.
  • the stability of the CB-Anti-0001 antibody was verified by the accelerated destruction method, that is, (1) the antibody stock solution was stored at 4°C for 14 days; (2) the antibody stock solution was placed in a constant temperature incubator at 37°C for 14 days; and (3) placing the antibody working solution (the antibody working solution obtained by diluting the antibody stock solution at a ratio of 1:2000 with Zhongshan Jinqiao ZLI-9028 antibody dilution solution) in a 37°C constant temperature incubator for 14 days. Under the same experimental conditions, the aforementioned three types of antibody solutions were used for IHC detection to evaluate the stability of the antibodies under the three treatment methods.
  • FIG. 4A is the IHC of the CB-Anti-0001 antibody stock solution stored at 4°C for 14 days.
  • Fig. 4B shows the IHC results of the CB-Anti-0001 antibody stock solution stored at 37°C for 14 days
  • Fig. 4C shows the IHC results of the CB-Anti-0001 antibody working solution stored at 37°C for 14 days). It can be seen that after the CB-Anti-0001 antibody working solution was stored at 37°C for 14 days, the antibody was still stable and retained good detection ability.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PCT/CN2022/071976 2021-01-15 2022-01-14 抗trpv6单克隆抗体及其应用 Ceased WO2022152236A1 (zh)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CN202280010293.4A CN116802277A (zh) 2021-01-15 2022-01-14 抗trpv6单克隆抗体及其应用
CA3206472A CA3206472A1 (en) 2021-01-15 2022-01-14 Anti-trpv6 monoclonal antibody and application thereof
KR1020237022218A KR20230132450A (ko) 2021-01-15 2022-01-14 항trpv6 단일 클론 항체 및 그 응용
EP22739112.5A EP4293044A4 (en) 2021-01-15 2022-01-14 MONOCLONAL ANTI-TRPV6 ANTIBODY AND USE THEREOF
US18/261,489 US20260116965A1 (en) 2021-01-15 2022-01-14 Anti-trpv6 monoclonal antibody and application thereof
JP2023542926A JP2024505430A (ja) 2021-01-15 2022-01-14 抗ｔｒｐｖ６モノクローナル抗体及びその応用

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CNPCT/CN2021/072249 2021-01-15
CN2021072249 2021-01-15
CN202210029357.7 2022-01-11
CN202210029357 2022-01-11

Publications (1)

Publication Number Publication Date
WO2022152236A1 true WO2022152236A1 (zh) 2022-07-21

Family

ID=82447968

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2022/071976 Ceased WO2022152236A1 (zh) 2021-01-15 2022-01-14 抗trpv6单克隆抗体及其应用

Country Status (8)

Country Link
US (1) US20260116965A1 (https=)
EP (1) EP4293044A4 (https=)
JP (1) JP2024505430A (https=)
KR (1) KR20230132450A (https=)
CN (1) CN116802277A (https=)
CA (1) CA3206472A1 (https=)
TW (1) TW202246332A (https=)
WO (1) WO2022152236A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023062226A3 (en) * 2021-10-14 2023-05-25 Universite De Lille Antibodies against extracellular epitopes of human trpv6 channel and their diagnostic and therapeutic uses

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1483740A (zh) * 2002-09-16 2004-03-24 上海新世界基因技术开发有限公司 具有抑癌功能的新的人蛋白及其编码序列
US20150182644A1 (en) * 2009-06-26 2015-07-02 Soricimed Biopharma Inc. Compounds and methods for the detection of trpv-6 cancers and drug delivery
CN105399798A (zh) * 2015-11-24 2016-03-16 广东药学院 Trpc3抗原多肽和抗trpc3的单克隆抗体

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022365387A1 (en) * 2021-10-14 2024-05-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies against extracellular epitopes of human trpv6 channel and their diagnostic and therapeutic uses

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1483740A (zh) * 2002-09-16 2004-03-24 上海新世界基因技术开发有限公司 具有抑癌功能的新的人蛋白及其编码序列
US20150182644A1 (en) * 2009-06-26 2015-07-02 Soricimed Biopharma Inc. Compounds and methods for the detection of trpv-6 cancers and drug delivery
CN105399798A (zh) * 2015-11-24 2016-03-16 广东药学院 Trpc3抗原多肽和抗trpc3的单克隆抗体

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
AL-LAZIKANI, B., CHOTHIA, C., LESK, A.M., J. MOL. BIOL., vol. 273, no. 4, 1997, pages 927
CHOTHIA, C ET AL., J MOL BIOL, vol. 186, no. 3, 1985, pages 651 - 63
CHOTHIA, C ET AL., NATURE, vol. 31, no. 6252, 1989, pages 877 - 83
CHOTHIA, CLESK, A.M., J.MOL.BIOL., vol. 196, 1987, pages 901
DATABASE NUCLEOTIDE 7 October 2008 (2008-10-07), ANONYMOUS : "Homo sapiens mRNA for transient receptor potential channel 6, subfamily V, (TRPV6 gene)", XP055950245, retrieved from NCBI Database accession no. AJ243501 *
HIRNET DANIELA, OLAUSSON JENNY, FECHER-TROST CLAUDIA, BÖDDING MATTHIAS, NASTAINCZYK WOLFGANG, WISSENBACH ULRICH, FLOCKERZI VEIT, F: "The TRPV6 gene, cDNA and protein", CELL CALCIUM, ELSEVIER, AMSTERDAM, NL, vol. 33, no. 5-6, 1 May 2003 (2003-05-01), AMSTERDAM, NL, pages 509 - 518, XP055950252, ISSN: 0143-4160, DOI: 10.1016/S0143-4160(03)00066-6 *
IWATA, Y. ET AL.: "Production of TRPV2-targeting functional antibody ameliorating dilated cardiomyopathy and muscular dystrophy in animal models", LABORATORY INVESTIGATION, vol. 100, 2 January 2020 (2020-01-02), XP036998398, DOI: 10.1038/s41374-019-0363-1 *
KABAT E.A ET AL., NATIONAL INSTITUTES OF HEALTH, BETHESDA, MD, 1991
STUMPF TOBIAS, ZHANG QI, HIRNET DANIELA, LEWANDROWSKI URS, SICKMANN ALBERT, WISSENBACH ULRICH, DÖRR JANKA, LOHR CHRISTIAN, DEITMER: "The Human TRPV6 Channel Protein Is Associated with Cyclophilin B in Human Placenta", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, vol. 283, no. 26, 1 June 2008 (2008-06-01), US , pages 18086 - 18098, XP055950249, ISSN: 0021-9258, DOI: 10.1074/jbc.M801821200 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023062226A3 (en) * 2021-10-14 2023-05-25 Universite De Lille Antibodies against extracellular epitopes of human trpv6 channel and their diagnostic and therapeutic uses

Also Published As

Publication number Publication date
JP2024505430A (ja) 2024-02-06
CN116802277A (zh) 2023-09-22
TW202246332A (zh) 2022-12-01
CA3206472A1 (en) 2022-07-21
EP4293044A4 (en) 2025-05-28
US20260116965A1 (en) 2026-04-30
KR20230132450A (ko) 2023-09-15
EP4293044A1 (en) 2023-12-20

Similar Documents

Publication Publication Date Title
CA3027417C (en) Anti-human trop-2 antibody having an antitumor activity in vivo
JP4620591B2 (ja) ヒトインスリン様成長因子に対する遺伝子組換え抗体
JP6980075B2 (ja) がん細胞特異的な抗体、抗がん剤、及びがんの検査方法
JPWO2003093317A1 (ja) ヒトインスリン様成長因子に対する抗体
JPWO2020026987A1 (ja) 抗ｒｏｒ１モノクローナル抗体およびその機能的断片、遺伝子、薬剤デリバリー組成物、並びに、医薬組成物
CN110691793A (zh) 黏结蛋白聚糖-1（cd138）结合剂及其用
TWI790992B (zh) 抗ｔｍｅｍ-１８０抗體、抗癌劑、及癌之檢查方法
JP7229503B2 (ja) ＣＡＤＭ１ｖ９認識抗体
WO2014169494A1 (zh) 特异性识别egfr突变蛋白的单克隆抗体、制备方法及其应用
WO2022152236A1 (zh) 抗trpv6单克隆抗体及其应用
KR20130135869A (ko) 항 단쇄 제4형 콜라겐 폴리펩타이드 항체 및 이를 포함하는 종양의 진단, 예방 또는 치료용 약제
WO2014047973A1 (zh) 特异性识别B-Raf突变蛋白的单克隆抗体、制备方法及其应用
WO2006123829A1 (ja) ＰＡＰ２ａに対する抗体ならびにその診断的および治療的使用
US8093361B2 (en) Anti-perp antibody
JP2019050737A (ja) Ｃｄ４４陽性ｔｍｅｍ−１８０陽性のがん細胞由来微粒子、これを用いた抗ｔｍｅｍ−１８０抗体療法が有効ながん患者の選別方法、選別された患者に対する抗ｔｍｅｍ−１８０抗体を含む抗がん剤、および前記方法に用いるキット
HK40105295A (en) Anti-trpv6 monoclonal antibody and application thereof
JP2007320850A (ja) 抗エフリンｂ２抗体
KR20260028757A (ko) 항-cldn18.2 항체 및 이의 진단적 용도
HK40123863A (zh) 抗cldn18.2抗体及其诊断用途
NZ716839B2 (en) Anti-human trop-2 antibody having an antitumor activity in vivo
NZ716839A (en) Anti-human trop-2 antibody having an antitumor activity in vivo
HK1198042A (en) Anti-human trop-2 antibody exhibiting antitumor activity in vivo
NZ623464B2 (en) Anti-human trop-2 antibody having an antitumor activity in vivo
HK1198042B (en) Anti-human trop-2 antibody exhibiting antitumor activity in vivo

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22739112

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3206472

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 202280010293.4

Country of ref document: CN

Ref document number: 2023542926

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2022739112

Country of ref document: EP

Effective date: 20230816

WWW Wipo information: withdrawn in national office

Ref document number: 1020237022218

Country of ref document: KR